A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00543920|
Recruitment Status : Completed
First Posted : October 15, 2007
Last Update Posted : November 26, 2015
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
|Condition or disease||Intervention/treatment||Phase|
|Anxiety Disorders||Drug: MK0777||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||August 2002|
|Actual Primary Completion Date :||February 2003|
|Actual Study Completion Date :||February 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543920
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|